Tags

Type your tag names separated by a space and hit enter

Efficacy of the novel camptothecin gimatecan against orthotopic and metastatic human tumor xenograft models.
Clin Cancer Res. 2004 Nov 01; 10(21):7357-64.CC

Abstract

PURPOSE

Gimatecan, a novel oral lipophilic camptothecin characterized by favorable features at molecular/cellular level and by a promising profile of preclinical activity, is currently in clinical phase I/II. The aim of the study was to additionally investigate the therapeutic potential of the drug in human tumor xenografts growing in different organs as models representative of tumor growth in the clinical setting.

EXPERIMENTAL DESIGN

The models include two orthotopic central nervous system tumors, two melanomas growing intracranially, and an ovarian carcinoma growing i.p. In addition, gimatecan was tested against experimental lung metastases of two tumor types (lung and ovarian carcinomas). Gimatecan was delivered by oral gavage according to various schedules (daily or intermittent). The time (in days) mice required to show evident signs of disease was used as end point for drug efficacy.

RESULTS

Gimatecan was highly effective in delaying disease manifestations in all tumor systems investigated. In the intracranially growing tumors, a significant time increase (versus control mice) was achieved by the drug administered according to all of the schedules. In addition, almost all treated mice were alive and tumor-free at the end of the experiment in the metastatic models and in the ascitic ovarian tumor. The daily prolonged treatment schedule was the best one.

CONCLUSIONS

In all tumor systems investigated, including orthotopic tumor growth models and lung metastases, the oral administration of gimatecan showed a therapeutic benefit in terms of survival increase. The good oral availability allowed a prolonged daily treatment regimen, which seems the most promising to exploit the therapeutic potential of the drug.

Authors+Show Affiliations

Istituto Nazionale Tumori, Milan, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15534112

Citation

De Cesare, Michelandrea, et al. "Efficacy of the Novel Camptothecin Gimatecan Against Orthotopic and Metastatic Human Tumor Xenograft Models." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, vol. 10, no. 21, 2004, pp. 7357-64.
De Cesare M, Pratesi G, Veneroni S, et al. Efficacy of the novel camptothecin gimatecan against orthotopic and metastatic human tumor xenograft models. Clin Cancer Res. 2004;10(21):7357-64.
De Cesare, M., Pratesi, G., Veneroni, S., Bergottini, R., & Zunino, F. (2004). Efficacy of the novel camptothecin gimatecan against orthotopic and metastatic human tumor xenograft models. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 10(21), 7357-64.
De Cesare M, et al. Efficacy of the Novel Camptothecin Gimatecan Against Orthotopic and Metastatic Human Tumor Xenograft Models. Clin Cancer Res. 2004 Nov 1;10(21):7357-64. PubMed PMID: 15534112.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy of the novel camptothecin gimatecan against orthotopic and metastatic human tumor xenograft models. AU - De Cesare,Michelandrea, AU - Pratesi,Graziella, AU - Veneroni,Silvia, AU - Bergottini,Raffaella, AU - Zunino,Franco, PY - 2004/11/10/pubmed PY - 2005/5/4/medline PY - 2004/11/10/entrez SP - 7357 EP - 64 JF - Clinical cancer research : an official journal of the American Association for Cancer Research JO - Clin. Cancer Res. VL - 10 IS - 21 N2 - PURPOSE: Gimatecan, a novel oral lipophilic camptothecin characterized by favorable features at molecular/cellular level and by a promising profile of preclinical activity, is currently in clinical phase I/II. The aim of the study was to additionally investigate the therapeutic potential of the drug in human tumor xenografts growing in different organs as models representative of tumor growth in the clinical setting. EXPERIMENTAL DESIGN: The models include two orthotopic central nervous system tumors, two melanomas growing intracranially, and an ovarian carcinoma growing i.p. In addition, gimatecan was tested against experimental lung metastases of two tumor types (lung and ovarian carcinomas). Gimatecan was delivered by oral gavage according to various schedules (daily or intermittent). The time (in days) mice required to show evident signs of disease was used as end point for drug efficacy. RESULTS: Gimatecan was highly effective in delaying disease manifestations in all tumor systems investigated. In the intracranially growing tumors, a significant time increase (versus control mice) was achieved by the drug administered according to all of the schedules. In addition, almost all treated mice were alive and tumor-free at the end of the experiment in the metastatic models and in the ascitic ovarian tumor. The daily prolonged treatment schedule was the best one. CONCLUSIONS: In all tumor systems investigated, including orthotopic tumor growth models and lung metastases, the oral administration of gimatecan showed a therapeutic benefit in terms of survival increase. The good oral availability allowed a prolonged daily treatment regimen, which seems the most promising to exploit the therapeutic potential of the drug. SN - 1078-0432 UR - https://www.unboundmedicine.com/medline/citation/15534112/Efficacy_of_the_novel_camptothecin_gimatecan_against_orthotopic_and_metastatic_human_tumor_xenograft_models_ L2 - http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=15534112 DB - PRIME DP - Unbound Medicine ER -